GlaxoSmithKline and Vir Biotechnology have taken a big step toward authorization of an intramuscular formulation of their anti-SARS-CoV-2 antibody sotrovimab. The partners have filed for FDA emergency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback